J. Ladero

Hepatitis Monthly · 2011

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.

Whom J. Ladero trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. L. Seeff

Who trusts J. Ladero overall

  1. Yukinori Koyama
  2. D. Brenner
  3. A. Calcinotto

Papers from J. Ladero's perspective

Ordered by how strongly the researchers J. Ladero trusts endorse each paper. Same corpus, a different order for every researcher.

  1. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy (Nature Genetics)
  2. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (Gastroenterology)
  3. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. (Gastroenterology)
  4. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance (Nature)
  5. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus (Nature)
  6. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an… (The Lancet)
  7. Telaprevir for retreatment of HCV infection. (New England Journal of Medicine)
  8. Risk Factors of Cholangiocarcinoma (Hepatology)
  9. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. (Gastroenterology)
  10. The epidemiology of cholangiocarcinoma. (Seminars in liver disease (Print))

Their papers